A Single-center, Randomized, Double-blind, Flexible-dosage, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
Latest Information Update: 14 Jan 2020
At a glance
- Drugs SKL 15508 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors SK Life Science
- 24 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Nov 2014 Planned End Date changed from 1 Dec 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 20 Nov 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.